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Abstract Introduction: The European Medical Information Framework consortium has assembled electronic
health record (EHR) databases for dementia research. We calculated dementia prevalence and
incidence in 25 million persons from 2004 to 2012.
Methods: Six EHR databases (three primary care and three secondary care) from five countries were
interrogated. Dementia was ascertained by consensus harmonization of clinical/diagnostic codes.
Annual period prevalences and incidences by age and gender were calculated and meta-analyzed.
Results: The six databases contained 138,625 dementia cases. Age-specific prevalences were around
30% of published estimates from community samples and incidences were around 50%. Pooled
prevalences had increased from 2004 to 2012 in all age groups but pooled incidences only after
age 75 years. Associations with age and gender were stable over time.
Discussion: The European Medical Information Framework initiative supports EHR data on unprec-
edented number of people with dementia. Age-specific prevalences and incidences mirror estimates
from community samples in pattern at levels that are lower but increasing over time.
*Corresponding author. Tel.: 144-20-7848-0120; Fax: 144-20-7848-
5408.
E-mail address: robert.stewart@kcl.ac.uk
http://dx.doi.org/10.1016/j.jalz.2017.06.2270
1552-5260/ 2017 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Electronic health records (EHRs) are increasingly
replacing paper records across health care sectors, creating
large volumes of digitized data on real-world clinical inter-
ventions and outcomes. Applications of such data extend
beyond clinical care to planning and costing health services,
and health surveillance. For research, EHR-derived
databases offer large sample sizes and are particularly suited
to investigations of intervention outcomes in routine care,
such as predictors of response, safety, comparative effective-
ness, and health economic evaluations, as well as etiologic
investigations of rare exposures/outcomes.
EHRs have been underused in dementia research,
although examples include identification in primary care
[1], resource use in Alzheimer’s disease [2], comorbidities
[3], case capture efficiency [4], dementia incidence [5],
dementia-free life expectancy [6], risks associated with
medication exposures [7] and other disorders [8], atypical
antipsychotics and mortality in vascular dementia [9], and
cognitive trajectories before and after acetylcholinesterase
inhibitor initiation [10].
EHR data on dementia, as with most clinical research
data, are limited to people who have received a diagnosis.
These are a subset of people living with dementia in the com-
munity, many of whom will not receive a diagnosis and can
only be ascertained in surveys applying case-ascertainments.
However, epidemiologic studies of dementia tend to focus
on incidence and risk factors (i.e., investigating up to the
point of onset), and most research on dementia outcome,
including service costs, involves cohorts who have received
a clinical diagnosis rather than screened community
samples. The relationships between community incidence/
prevalence and incidence/prevalence of diagnosed dementia
are therefore important to understand because of these
different samples. Such relationships may vary both
geographically and temporally: settings with active demen-
tia diagnosis centers are likely to see a higher proportion of
community cases appear on health care databases, and these
are likely to increase over timewith greater public awareness
and a higher salience in primary care.
Advances in medical research require an increasing
quantity and detail of health data to answer today’s complex
questions. At the same time, huge volumes of health data are
being collected and electronically stored, either in routine
EHR databases or through research-driven cohort studies
associated with biobanks and other efforts. To help improve
access to patient-level data, the European Medical Informa-
tion Framework (EMIF) was launched in 2013. As part of the
broader European Innovative Medicines Initiative, EMIF
aims to create an environment that allows efficient reuse of
health data in two therapeutic areas: Alzheimer’s disease
and metabolic disorders. In the first year of operation,
EMIF explored several EHR resources to render data avail-
able for analysis with robust data security and governance. In
this study, we provide initial data on number of cases of
dementia detected on six EHR sources—three primary
care and three secondary care. Our objective was partly to
describe this data resource and partly to provide prevalence
and incidence estimates for diagnosed dementia in European
populations, comparing these across the different databases
and years of data collection.
2. Methods
2.1. Databases
Using the collaborations and platform for analysis set up
by EMIF, the following six EHR databases were interrogated:
(1) Agenzia regionale di sanita della Toscana (ARS), (2)
Aarhus University Hospital (AUH), (3) the Health Search
Database (GENOMEDICS), (4) the Information System of
Parc de Salut Mar (IMIM-UPF), (5) Integrated Primary
Care Information (IPCI), and (6) The Health Improvement
Network (THIN). Characteristics of databases are summa-
rized in Table 1. Number of active patients on each database
on January 1, 2013 varied from around 900,000 inGENOME-
DICS to around 3.8 million in THIN.
2.1.1. Catchment databases
The ARS database contains secondary health care data
from the Tuscany region of Italy, including pharmacy,
outpatient and hospital data along with linked data on death,
and birth and malformation registries. The AUH database
contains data from secondary health care registries covering
the northern and central region of Jutland, Denmark,
including information on all inpatient, emergency room,
and outpatient visits, inpatient treatments, laboratory data,
and prescriptions. The IMIM-UPF database contains second-
ary health care data from the Barcelona area, including acute,
long term, and mental health services with information on
inpatient, emergency room, and outpatient visits.
2.1.2. Primary care databases
IPCI, GENOMEDICS, and THIN contain primary care
data from selected general practices in the Netherlands,
Italy, and United Kingdom, respectively.
Considering broader health care settings, Italy has a
government-funded universal health care system in which
free health care is provided to all citizens, all persons in Italy
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Table 1
Characteristics of the electronic health record databases participating in the study
Characteristics ARS AUH GENOMEDICS IMIM-UPF IPCI THIN
Geographic origin of data Tuscany, Italy Northern and central
region of Jutland,
Denmark
Italy Barcelona, Spain Netherlands UK (England, Northern
Ireland, Scotland, and
Wales)
Source of data Administrative/billing
data on general
pharmacy; inhabitant
registry; outpatient
care; hospital
admission
Emergency ward; general
pharmacy; hospital
admission; inhabitant
registry
Primary care records Emergency ward; hospital
admission; outpatient
care
Primary care records Primary care records
Year of initial data
collection
1996 1996 1998 1990 1995 2002
Reasons for entry/exit Patient moves in or out a
specific geographical
area
Patient moves in or out a
specific geographical
area
Patient enters or leaves the
practice of a general
practitioner
Hospital admission/
discharge
Patient enters or leaves the
practice of a general
practitioner
Patient enters or leaves the
practice of a general
practitioner
Approximate total
(cumulative) number of
patients
5 millions 2.3 million 2.3 million More than 1 million 2.8 million 12 million
Approximate number of
active patients as at
January 2013
3.6 million 1.8 million 900,000 513,000 1.8 million 3.8 million
Average follow-up period
per patient in years
9 y 13 y 10 y 4.75 y 3 y, but with a wide range Median follow-up of
active patients is 9 y
Primary sources of
clinical diagnoses
Death registry; inpatient
care; exemptions from
copayment
Outpatient care; inpatient
care; emergency care;
death registry;
procedure registry
Primary care Death registry; procedure
registry; inpatient care;
emergency care;
outpatient care
Primary care and
communications to/
from secondary care
Primary care
Terminology system(s)
used to store diagnoses
ICD-9 ICD-10 ICD-9 ICD-9 Free text, codes from
Dutch College of
General Practitioners,
International
Classification of
Primary Care
READ codes, free text
Death recorded Yes Yes Yes Yes Yes Yes
NOTE. Databases: (1) Agenzia regionale di sanita della Toscana (ARS), (2) Aarhus University Hospital (AUH), (3) the Health Search Database (GENOMEDICS), (4) the Information System of Parc de Salut
Mar (IMIM-UPF), (5) Integrated Primary Care Information (IPCI), (6) The Health Improvement Network (THIN).
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are registered with a general practitioner (GP) who acts as a
gatekeeper for all primary care health care services, the system
is mostly region-based although citizens may access (free of
charge) any hospital in Italy Q5. The Danish National Health Ser-
vice provides universal tax-supported health care, guaranteeing
unfettered access to GPs and hospitals, and partial reimburse-
ment for prescribed medications, and accurate linkage of all
registries at the individual level is possible in Denmark using
the unique Central Personal Register number assigned to
each Danish citizen at birth and to residents on immigration.
The Spanish health care system consists of both private and
public health care (although more than 90% of the population
makes use of the public system for their medical care), the
financing of the health care system is the responsibility of
the National Health System and the autonomous communities
and is based on a universal coverage model, although informa-
tion linkage between health care levels and autonomous
communities’ EHR systems is not complete. In the
Netherlands, all citizens are registered with one GP, who forms
the first point of care for all medical complaints, and electronic
medical records contain all journal entries written by the GPs,
and coded and anonymous data on patient demographics,
diagnoses using the International Classification for Primary
Care, referrals, laboratory findings, and drug prescriptions.
The UK has a government-funded National Health Service
delivering health care free at the point of delivery, although
with standard charges for some services (e.g., dentistry) and
prescription medication, and with GP referral required for all
nonemergency secondary care.
2.2. Dementia definitions
Codes used to identify dementia are detailed inAppendixA.
The aim for the databases was to capture as broad as possible a
range of indicators, whereas restricting to those that clearly
indicated a dementia diagnosis, rather than those that were sug-
gestive. Therefore we opted not, at this stage, to define demen-
tia subgroups, on the assumption that more specific diagnoses
would bemore likely to have higher heterogeneity. The process
of code assembly was a reciprocal one between academics and
database holders, based on knowledge of dementia diagnoses
and of local clinical practice. The Unified Medical Language
System was used to identify medical concepts and correspond-
ing codes in each terminology, and a common database model
was used to share and pool data and verify the semantic basis of
the event extraction queries [11]. Beginning with long lists of
terms from constituent databases and diagnostic systems, feed-
back from the database holders was obtained at several stages
to refine the extraction queries, and definitions were finalized
by consensus.
2.3. Prevalence and incidence calculations
Definitions used for case prevalence and incidence
estimations are summarized in Table 2. We computed
database- and year-specific annual incidences and periodTa
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prevalences by age and gender for each database and for
each calendar year, restricting the analyses to the calendar
years 2004 to 2012 when data were available from all
sources. Denominator populations for the three catchment
databases (ARS, AUH, and IMIM-UPF) are defined from
resident lists (inhabitant registries; see Table 1), regardless
of health care contact and were ascertained for the calendar
years described in this analysis based on routinely recorded
and updated entry/exit dates (from the catchment) and
national mortality records. Denominator populations for
the primary care databases consist of total populations regis-
tered, again updated for each year of analysis by entry and
exit dates (including mortality). The date of the first recorded
dementia coding for a given person within each database
(across all years of data since initial collection—see
Table 1) was therefore ascertained and these provided the
numerator population for incidence estimates (i.e., for the
respective calendar years of the first dementia coding),
with the denominator population defined for that year in
the catchment or primary care database, having taken into
account entry and exit dates. Each case of dementia then
contributed to prevalence estimates (applying the same
year-specific denominators) from the age at first diagnosis
to the age at exit. Denominator populations were further sub-
classified by age ranges at the mid-point for each year and
both numerator and denominator samples were restricted
to people aged 50 years or older at respective time points.
2.4. Analysis
The following output was generated and displayed graphi-
cally: (1) case prevalence and incidence by age group and year
for each database; (2) case prevalence and incidence by age
group and database for each year of calculation; and (3) female
to male ratios of prevalence and incidence by year for each
database. As an initial summary, a table was generated, which
contained annual period prevalence, annual incidence, and
female to male ratio statistics of these two estimates, by age
group and database, averaged across the 9 years of
observation. Prevalences and incidences were then meta-
analyzed across databases using random-effects models
(because of observed high levels of heterogeneity) and pooled
estimates graphically displayed by age group and year. This
was followed by ameta-analysis of individual linear regression
coefficients of logged prevalence or incidence outcomes
against age group increments, approximate estimates of asso-
ciations with age. I2 statistics were calculated in all instances
as estimates of heterogeneity. Final analyses estimated case
duration (approximating survival after diagnosis) by dividing
prevalence and annual incidence (percentages), displaying
these for age groups by database and year.
3. Results
A number of cases detected with dementia in each data-
base from 2004 to 2012 are displayed in Table 3. A total
of 138,625 cases were represented, varying from 1566 in
the IMIM-UPF database to 52,296 in ARS. Illustrative
data on periods of time represented before and after the first
dementia diagnosis are likewise displayed. Overall, the total
number of person-years was estimated to be more than 1
million before the first diagnosis and more than 400,000
Table 3
Distribution of data availability before and after the index date (first instance of recorded dementia) for cases in EMIF-AD EHR databases
Database
Number with dementia
2004–2012
Years of data before diagnosis for individuals with
dementia
Years of data after diagnosis for individuals with
dementia
Mean SD Range Total person-years Mean SD Range Total person-years
ARS 52,296 4.66 2.65 0–9 244,828 2.09 2.18 0–9 109,649
AUH 20,765 4.88 2.82 0–10 111,976 2.67 2.22 0–10 61,300
GENOMEDICS 13,826 5.52 3.40 0–12 98,427 3.35 2.70 0–12 59,700
IMIM-UPF 1566 6.40 4.84 0–22 17,936 0.85 1.62 0–14 2390
IPCI 6128 2.29 1.81 0–11 19,814 1.46 1.26 0–9 12,583
THIN 44,044 8.13 5.71 0–26 556,964 2.28 2.25 0–22 156,202
Combined data 138,625 5.80* 3.71* 0–26 1,049,945 2.32* 2.21* 0–14 401,824
Abbreviations: EHR, electronic health record; EMIF, European Medical Information Framework; SD, standard deviation Q8.
NOTE. Databases: (1) Agenzia regionale di sanita della Toscana (ARS), (2) Aarhus University Hospital (AUH), (3) the Health Search Database (GENOME-
DICS), (4) the Information System of Parc de Salut Mar (IMIM-UPF), (5) Integrated Primary Care Information (IPCI), (6) The Health Improvement Network
(THIN).
*Arithmetically weighted by case numbers.
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Fig. 1. Pooled dementia prevalence by age group and year. A logarithmic y-
axis scale is used to enable relative time trends to be compared between age
groups.
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after this date; mean follow-up periods for the six databases
averaged 5.3 and 2.1 years, respectively.
Pooled prevalences and incidences of dementia by age
group and year, meta-analyzed across databases are
displayed in Figs. 1 and 2 and detailed in Table B1 of
Appendix B. Because we wanted to visualize relative
changes in estimates over the sampled years, logarithmic
scales were used for the y-axes to illustrate such changes
in different age groups. High levels of heterogeneity were
found for all cells: I2 statistics were.95% for all prevalence
estimates and .90% for all incidence estimates apart from
those in the 50- to 54-year-old age group, which ranged
from 50% to 87%. For dementia prevalence estimates,
reasonably consistent increases across the years analyzed
were observed in most age groups; however, these period ef-
fects were only evident for dementia incidence estimates in
older age groups. Pooled associations with age are displayed
in Table B2 of Appendix B. From I2 estimates, considering
the final column, coefficients showed a high level of
homogeneity between years for all databases apart from
IMIM-UPF (which also had the smallest slope coefficients).
On the other hand, considering pooled estimates by year,
between-database heterogeneity was frequently marked,
tended to be lowest in earlier years and highest in more
recent years. Considering the coefficients themselves, there
were no noticeable trends across the years analyzed.
Estimated annual period prevalence and incidence of
dementia averaged across the observed years and stratified
by database are given in Table 4; they are further displayed
by age and year for each database in Figs. C1 and C2 of
Appendix C and by age and database for each year in
Figs. C3 and C4 of Appendix C. All databases showed
increases in prevalence and incidence by age and generally
patterns were similar, particularly across the larger databases.
Most databases also appear to show a leveling off of preva-
lence and incidence trajectories in the oldest age group—in
that estimates for the 951 age group are lower than would
be expected from curve trajectories in preceding age groups.
Prevalences varied around twofold across databases: for
example for 85- to 89-year olds, mean 1-year period
prevalences ranged from 4.9% to 9.4% and mean annual inci-
dences from 1793 to 3650 per 100,000 person-years (Table 4).
Female to male prevalence ratios are displayed in Fig. C5 of
Appendix C; these showed a modest increase across age
groups from equality in younger age groups to a female pre-
dominance in older age groups, but little or no change over the
years sampled, particularly in the larger data sets. Female to
male incidence ratios (Fig. C6 of Appendix C) were closer
to unity, did not change substantially over time, and only
increased slightly in strength across the age range.
Estimated case duration is summarized in Appendix D.
Modest increases were seen over time for most age groups,
of the order of half a year improvement from 2004 to 2012
(Table D1 and Fig. D1 of Appendix D). Marked heterogene-
ity, however, was observed between databases with lowest
duration in IMIM-UPF and highest in GENOMEDICS.
Associations with age were not consistent between databases.
4. Discussion
The EMIF consortium has assembled what we believe
may be the world’s largest EHR resource for dementia
research, and the primary objective of this initial study
was to describe prevalences and incidences of cases across
data sets and years of data collection. Random-effects
meta-analyses indicated increasing prevalences across the
9 years analyzed but less marked increases in incidences
apart from in older age groups, high between-database het-
erogeneity for prevalence/incidence estimates, andmoderate
heterogeneity for age-associated trajectories (highest in
more recent years), but homogeneity of between-year age-
associated trajectories. Gender ratios were relatively stable
by database and time. Estimated case duration increased
over time, did not vary consistently with age, and was
heterogeneous between databases.
A recent systematic review of community surveys in Eu-
rope estimated dementia prevalences (%) to be 0.2, 1, 4, 8,
13, 21, 32, and 45 in 60 to 65, 65 to 70, 70 to 75, 75 to 80,
80 to 85, 85 to 90, 90 to 95, and 951 age groups, respectively
[12]. Taking the most recent 2012 data, our pooled dementia
prevalence estimates from EHRs are 0.2, 0.4, 1, 2, 5, 8, 10,
and 11 for these respective age groups—i.e., 100%, 40%,
25%, 25%, 38%, 38%, 31%, and 24% of estimates from com-
munity samples. These discrepancies are more marked than a
50% underestimation suggested by other direct comparisons of
administrative and community data [13], but are similar to
2005 estimates from Danish hospital registers [14]. Our
dementia incidence rates were also similar to these Danish
data [14] and to ranges reported for people aged 651 from
US health care data [5]. Considering community studies of
dementia incidence, estimates from EURODEM were Q6205,
489, 1623, 2975, and 5356 per 100,000 person-years in age
groups 65 to 69, 70 to 74, 75 to 79, 80 to 84, and 85 to 89,
respectively [15]. Our 2012 pooled estimates for these age
groups were 96, 274, 728, 1564, and 2595 respectively—i.e.,
47%, 56%, 45%, 53%, and 48% of the community estimates.
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Fig. 2. Pooled dementia incidence by age group and year. A logarithmic y-axis
scale is used to enable relative time trends to be compared between age groups.
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Differences in dementia prevalence and incidence can be
expected between EHR databases and screened community
samples. On the one hand, many people with dementia do
not receive a diagnosis, and not all diagnoses are recorded in
an accessible (i.e., structured) or sufficiently specific format
within an EHR. On the other hand, community surveys often
do not sample long-term care facilities, where dementia is
highly prevalent [16] and whose residents are more likely to
be represented in EHRs. Of interest, in the EMIF EHR samples
there was more underestimation of community dementia prev-
alence than incidence. This may reflect different underlying
reasons for discrepancies: prevalence underestimates being ac-
counted for by underdiagnosis and incidence underestimates
by differential survival (i.e., prediagnosis mortality). An
underestimated prevalence would have resulted from an over-
estimated denominator population, whereas the oppositewould
be more likely if there were problems with enumeration. An
overestimated denominator might have resulted from cases
being seen in alternative facilities, although this would have
given rise to a more visible difference between primary care
and hospital databases (because diagnoses would be expected
to be communicated to GPs regardless of their source).
Table 4
Averaged annual period prevalence and incidence between 2004 and 2012 by age and EHR database
Database Age
Total number of dementia
cases from 2004 to 2012
Averaged annual estimates from 2004 to 2012
Annual period
prevalence (%) (95%
CI)
Female to male
prevalence ratio
Annual incidence rate/
100,000 person-years
(95% CI)
Female to male
incidence ratio
ARS ,70 2659 0.1 (0.1–0.2) 0.9 30 (29–32) 0.8
70–74 3608 0.6 (0.6–0.7) 0.9 188 (182–194) 0.8
75–79 7926 1.5 (1.4–1.5) 1.1 479 (469–490) 1.0
80–84 13,917 3.0 (2.9–3.1) 1.3 1046 (1029–1063) 1.1
85–89 14,212 5.3 (5.1–5.4) 1.3 1898 (1867–1929) 1.1
90–94 7574 6.9 (6.6–7.1) 1.4 2464 (2409–2520) 1.1
951 2400 7.1 (6.7–7.5) 1.4 2004 (1925–2085) 1.1
AUH ,70 2183 0.3 (0.3–0.3) 0.7 58 (56–60) 0.8
70–74 2188 1.4 (1.3–1.5) 1.0 383 (367–399) 1.0
75–79 3965 3.2 (3.0–3.3) 1.2 915 (887–944) 1.1
80–84 5509 6.1 (5.8–6.3) 1.3 1789 (1743–1837) 1.1
85–89 4635 9.4 (9.0–9.8) 1.3 2637 (2562–2714) 1.1
90–94 1844 10.8 (10.2–11.5) 1.4 2628 (2511–2751) 1.1
951 441 10.1 (8.9–11.4) 1.4 2384 (2171–2617) 1.1
GENOMEDICS ,70 1139 0.2 (0.2–0.2) 1.2 45 (43–48) 1.2
70–74 1568 1.3 (1.2–1.4) 1.3 310 (295–326) 1.4
75–79 2862 3.1 (3.0–3.3) 1.4 685 (660–710) 1.3
80–84 3774 5.7 (5.5–6.0) 1.4 1222 (1183–1261) 1.3
85–89 2854 8.7 (8.3–9.1) 1.4 1793 (1729–1860) 1.2
90–94 1342 10.7 (10.0–11.4) 1.4 2215 (2100–2337) 1.1
951 287 12.1 (10.5–13.9) 1.6 2688 (2394–3017) 1.3
IMIM-UPF ,70 129 0.3 (0.1–0.7) 0.6 208 (175–247) 0.7
70–74 118 0.7 (0.4–1.0) 0.7 454 (379–543) 0.9
75–79 304 1.7 (1.3–2.2) 1.0 1049 (938–1174) 0.9
80–84 429 3.0 (2.4–3.7) 1.2 1937 (1762–2129) 1.1
85–89 400 4.9 (3.8–6.2) 1.6 3650 (3309–4026) 1.2
90–94 147 7.7 (5.4–10.6) 2.0 4427 (3766–5204) 1.4
951 39 10.9 (5.7–18.7) 0.8 5513 (4028–7545) 0.6
IPCI ,70 659 0.2 (0.2–0.3) 1.0 69 (64–74) 1.0
70–74 632 1.4 (1.2–1.6) 1.0 436 (404–472) 1.0
75–79 1210 3.0 (2.7–3.3) 1.0 1076 (1017–1138) 1.1
80–84 1632 5.7 (5.3–6.2) 1.1 2085 (1987–2189) 1.1
85–89 1283 8.2 (7.4–8.9) 1.1 3012 (2852–3182) 1.1
90–94 579 10.4 (9.1–11.9) 1.1 3968 (3658–4305) 1.1
951 133 11.0 (8.3–14.3) 1.7 4043 (3411–4792) 1.3
THIN ,70 3145 0.1 (0.1–0.2) 1.0 38 (37–40) 1.0
70–74 4055 0.9 (0.9–1.0) 1.1 292 (283–301) 1.1
75–79 8001 2.2 (2.1–2.3) 1.2 708 (692–723) 1.1
80–84 11,477 4.6 (4.4–4.7) 1.4 1389 (1364–1414) 1.2
85–89 10,739 7.9 (7.7–8.1) 1.6 2259 (2216–2302) 1.2
90–94 5125 11.0 (10.6–11.4) 1.6 2711 (2638–2786) 1.3
951 1502 12.2 (11.5–13.0) 1.7 2638 (2508–2775) 1.3
Abbreviations: CI, confidence interval; EHR, electronic health record.
NOTE. Databases: (1) Agenzia regionale di sanita della Toscana (ARS), (2) Aarhus University Hospital (AUH), (3) the Health Search Database (GENOMEDICS),
(4) the Information System of Parc de Salut Mar (IMIM-UPF), (5) Integrated Primary Care Information (IPCI), (6) The Health Improvement Network (THIN).
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Considering survival, postdiagnosis case duration was around
3 years inmost age groups,which is shorter than the 5 to 9 years
estimated from first symptom emergence [17,18] and which
might be accounted for by delayed diagnosis, although might
also reflect the capture of people with rapid-progression disor-
ders missed by conventional cohort studies [19].
Between-database heterogeneity was observed for demen-
tia prevalence and incidence estimates in all age groups. This
is likely to arise from between-database differences in clinical
ascertainment and/or recording of dementia rather than from
underlying differences in risk. Considering data sources, the
lowest prevalences in later years were consistently found in
two secondary care databases (ARS and IMIM-UPF), which
also tended to have the highest incidences, and later diagnosis
and lower case survival was evident for IMIM-UPF at least;
the other secondary care database (AUH) showed estimates
much closer to those from primary care, possibly reflecting
the additional use of outpatient records for case definition
(Table 2). The consistently higher prevalence of dementia at
the uppermost end of the age range in two primary care data-
bases (GENOMEDICS and THIN) might reflect institutional
facilities served by participating practices but might also
reflect the high postdiagnosis case duration in these databases
(Fig. D2 of Appendix D).
Danish register data [14] showed an upward trend in
dementia incidence and prevalence over time, assumed to
be due to improved access to diagnosis. Similarly, dementia
diagnoses recorded on death certificates have been increasing
[20,21]. Again, time trends are likely to be determined by
health service access/responsiveness rather than changes in
risk. In the EMIF databases, age-specific prevalences of de-
mentia increased formore than the 9 years analyzed; however,
incidence rates only increased in older age groups. One pos-
sibility is that dementia ascertainment by clinical services in
younger age groups has remained constant, but case survival
has been improving, accounting for increasing prevalence but
stable incidence in younger age groups; in older age groups
increases in both ascertainment/recording and case survival
would account for increased prevalence and incidence. In-
creases by year in case duration were observed across most
age groups, consistent with this and with at least one previous
report of improvement over time in dementia survival [22].
Despite lower prevalence/incidence, dementia associa-
tions with age and gender in the EMIF EHR databases
were similar to community estimates, for example,
increasing exponentially with age. Although underestima-
tions of community incidence were relatively constant
across age groups, these varied more for prevalence, being
strongest in 70- to 80-year olds. Considering the most recent
year of data, only two EHRs (THIN and GENOMEDICS,
both primary care) showed continued increases in preva-
lence into the 951 age group and only one (GENOME-
DICS) showed this for incidence (Figs. C3 and C4 of
Appendix C); however, it should be borne in mind that cell
sizes in the 951 age group are likely to have given unstable
estimates in the smaller databases (particularly IMIM-UPF
and IPCI), although ought to be robust in the larger ones
(ARS and THIN). Age-specific dementia prevalence is
generally found to be higher in women than men in commu-
nity studies, although differences range from 1% to 2%
[13,23–25] to a doubling or more [26–28]. Female to male
prevalence ratios in the EHR data rose with age, whereas
incidence ratios rose more modestly; this would be
consistent with increased duration of diagnosed dementia
in older women because of lower case mortality.
A major strength of these EHR resources is that they cover
large populations, with data accruing over long periods.
However, it is important to bear in mind the limitations of
routine data. In particular, dementia diagnosis and recording
may vary substantially between individuals, localities and
internationally, influenced, for example, by clinician attitudes
to the usefulness of the diagnosis, its requirement or not for
treatment initiation, family pressures to assign (or not) a diag-
nosis, and the clinical or research criteria adopted. In addition,
EHRs from nonspecialist care do not generally contain data
(e.g., from cognitive/functional assessments), which indicate
the dementia severity at diagnosis. Despite this, there are
important potential research applications. Investigations of
prognosis, impact, and intervention response are perhaps
themost important, because alternative data sources (random-
ized trials and conventional clinical cohorts) are limited in
size and generalizability. However, there are also possibilities
for novel risk factor research, particularly where these tend to
be well recorded in health records and missed in traditional
cohort studies. Medication exposures and comorbidities are
the most available data; however, data linkages offer novel
additional possibilities in individual settings. For example,
AUH can be linked to data on education, school performance,
income, employment, and retirement, to an increasing extent
over time, as well as potentially with comparable spouse and
sibling data; THIN data can likewise be linked to those from
the spouse, and thus, for example, there are important
opportunities for investigating the shared environment or
the influence of one person’s dementia on another’s.
In summary, we describe trends in dementia prevalence
and incidence extracted from what collectively may form
the world’s largest database on this condition. EHR data
contain a wealth of longitudinal information on very large
samples, although limitations inherent in administrative in-
formation resources need to be borne in mind when studies
are designed to use these.
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RESEARCH IN CONTEXT
1. Systematic review: Using PubMed for English lan-
guage publications, we identified and reviewed all
publications on incidence and prevalence of demen-
tia in Europe, focusing on health records databases.
2. Interpretation: Analyses of 138,625 dementia cases
demonstrated age-associated increases in prevalence
and incidence followed by a flattening of trajectories in
oldest age groups, modest increases in prevalence
across the 9 years analyzed but relatively stable inci-
dence and strengths of association with age and gender.
3. Future directions: The European Medical Informa-
tion Framework consortium has assembled what we
believe may be the world’s largest electronic health
record resource for dementia research. This presents
potentially transformative opportunities in terms of
sample size and naturalistic follow-up, although
strengths and limitations of administrative data need
to be carefully considered in designing future pro-
jects using this resource.
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